Table 1.

Characteristics of the studies included in the meta-analyses

Reference	Trial name	Year	Phase	No. of patients	Drug combinations in arm 1	Drug combinations in arm 2	Patients with 1 previous treatment (%)	Patients with 2 or more previous treatments (%)
40	VANTAGE 088	2013	3	637	VOR/BOR	BOR	42	58
39	DOXIL-MMY-3001	2007	3	646	PLD/BOR	BOR	34	66
10	NCT00401843	2015	2	281	SIL/BOR	BOR	52	48
41	MMY 3021	2011	3	222	subBOR	BOR	63	37
37	AMBER	2012	2	102	BOR + BEV	BOR	48	52
36	ENDEAVOR	2015	3	929	CAR/DEX	BOR/DEX	50	50
35	PANORAMA 1	2014	3	768	PAN/BOR/DEX	BOR/DEX	51	49
34	CASTOR	2016	3	498	DAR/BOR/DEX	BOR/DEX	47	53
33	NCT01478048	2016	2	152	ELO/BOR/DEX	BOR/DEX	66	34
11	NCT00602511	2012	3	131	THA/DEX	BOR/DEX	NA	NA
32	MM-010	2007	3	351	LEN/DEX	DEX	32	68
31	MM-009	2007	3	353	LEN/DEX	DEX	38	62
29	APEX	2009	3	669	BOR	DEX	38	62
28	OPTIMUM	2012	3	499	THA	DEX	57	43
27	ASPIRE	2014	3	792	CAR/LEN/DEX	LEN/DEX	43	57
26	ELOQUENT-2	2015	3	646	ELO/LEN/DEX	LEN/DEX	48	52
42	TOURMALINE-MM1	2015	3	722	IXA/LEN/DEX	LEN/DEX	61	39
25	POLLUX	2016	3	569	DAR/LEN/DEX	LEN/DEX	52	48
24	MMVAR/IFM 2005-04	2012	3	269	BOR/THA/DEX	THA/DEX	53	47

BEV, bevacizumab; BOR, bortezomib; CAR, carfilzomib; DAR, daratumumab; DEX, dexamethasone; ELO, elotuzumab; IXA, ixazomib; LEN, lenalidomide; NA, not applicable; PAN, panobinostat; PLD, pegylated liposomal doxorubicin; SIL, siltuximab; subBOR, subcutaneous bortezomib; THA, thalidomide; VOR, vorinostat.